Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations

2001 ◽  
Vol 27 (3) ◽  
pp. 278-281 ◽  
Author(s):  
S.J. Ramus ◽  
A. Fishman ◽  
P.D.P. Pharoah ◽  
S. Yarkoni ◽  
M. Altaras ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Ashkenazi Jewish ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations ◽  
Ovarian Cancer Survival

BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Families with Breast and Ovarian Cancer

1997 ◽  
Vol 1 (1) ◽  
pp. 41-46 ◽  
Author(s):  
ELIZABETH L. SCHUBERT ◽  
HEATHER C. MEFFORD ◽  
JAMIE L. DANN ◽  
RHODORA H. ARGONZA ◽  
JUDY HULL ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ashkenazi Jewish ◽  
Breast And Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations ◽  
Jewish Families

BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features

2000 ◽  
Vol 10 (4) ◽  
pp. 289-295 ◽  
Author(s):  
A. Koul ◽  
S. Malander ◽  
N. Loman ◽  
T. Pejovic ◽  
S. Heim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

scholarly journals A MOLECULAR-BASED APPROACH TO INVESTIGATE BREAST CANCER 1 AND BREAST CANCER 2 STATUS IN OVARIAN CANCER AMONG IRAQI WOMEN

2018 ◽  
Vol 11 (7) ◽  
pp. 199
Author(s):  
Muhannad Shweash ◽  
Saddam Jumaa Naseer ◽  
Maisam Khider Al-anii ◽  
Thulfiqar Fawwaz Mutar
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Gene Mutations ◽  
Healthy Controls ◽  
Brca1 And Brca2 ◽  
First Degree Relatives ◽  
Brca Gene ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

Objective: Cancer ovary is one of the fatal gynecologic malignancies worldwide. Since breast cancer (BRCA) genes are considered tumor suppressor genes and play important roles in cancer by repairing of chromosomal damage with the error repair of DNA breaks. Therefore, breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) gene mutations strongly enhance the development of ovarian cancer risk among women. Here, we report that both genes are an essential mediator of progress ovarian cancer, to determine the influence of BRCA1 and BRCA2 mutations in the improvement of ovarian cancer.Methods: A total of 25 subjects were chosen for the genetic studies, and three groups were recruited: fifteen ovarian cancer patients group, five healthy controls, and five first-degree relatives to a known case of ovarian cancer patients.Results: A genetic analysis revealed that a strong correlation exists between both gene mutations’ status in ovarian cancer, and BRCA gene mutations (185delAG, 5382insC, and 4153delA in BRCA1 and 6174delT in BRCA2) remained to establish to have a relatively high frequency among people in this study among ovarian cancer patients. Furthermore, seven patients with ovarian cancer carried all of the four investigated mutations, and five had three mutations.Conclusion: Otherwise, BRCA gene frequency showed low prevalence among first-degree relatives, and to a lesser extent among healthy controls, with only a few had all of the mutations combined. These data demonstrate for the first time a molecular link between BRCA1 and BRCA2 mutations in ovarian cancer progression in Iraq.

scholarly journals Management of hereditary ovarian cancer

2011 ◽  
Vol 152 (40) ◽  
pp. 1596-1608 ◽  
Author(s):  
József Gábor Joó ◽  
Szabolcs Ládi ◽  
B. Zsolt Nagy ◽  
Zoltán Langmár
Keyword(s):  
Ovarian Cancer ◽  
Hereditary Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Ovarian Cancers ◽  
Brca2 Mutations ◽  
Histological Phenotype ◽  
Brca1 Brca2 ◽  
Brca1 And Brca2 Mutations ◽  
High Level ◽  
Associated Tumors

Mutations in BRCA1 and BRCA2 genes account for the majority of hereditary breast and ovarian cancers. Approximately 10% of cases of ovarian cancer are due to germline mutations in BRCA1 and BRCA2. Ovarian cancer associated with BRCA1 and BRCA2 mutations has a distinct histological phenotype. This type of cancer is predominantly of serous or endometrioid histology and is high grade. Patients with BRCA1 or BRCA2 mutations should be offered risk-reducing salpingo-oophorectomy by age 40 years, or when childbearing is complete. Nowadays there are no differences between the treatments provided for sporadic and hereditary ovarian cancer, although there are indications that targeted therapy is effective in women with BRCA1/BRCA2-associated tumors. Retrospective studies reveal a high level of sensitivity to platinum agents in BRCA-associated tumors and initial trials show good efficacy and tolerability for polyADP-ribose polymerase inhibitors in mutation carriers with advanced ovarian cancers. These agents might also potentially be used in chemoprevention. Authors review the current management of hereditary ovarian cancer. Orv. Hetil., 2011, 152, 1596–1608.

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients

2008 ◽  
Vol 113 (3) ◽  
pp. 467-477 ◽  
Author(s):  
Nan-Yan Rao ◽  
Zhen Hu ◽  
Wen-Feng Li ◽  
Juan Huang ◽  
Zhong-Liang Ma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Han Chinese ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations Missed Opportunities

2010 ◽  
Vol 65 (7) ◽  
pp. 436-437
Author(s):  
Larissa A. Meyer ◽  
Meaghan E. Anderson ◽  
Robin A. Lacour ◽  
Anuj Suri ◽  
Molly S. Daniels ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
Missed Opportunities ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations
Sign in / Sign up

Export Citation Format

Share Document